Takeda Pharmaceutical Co. $TAK Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership lifted its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 100.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,682,847 shares of the company’s stock after acquiring an additional 2,854,069 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.18% of Takeda Pharmaceutical worth $88,596,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in Takeda Pharmaceutical by 37.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 247,529 shares of the company’s stock valued at $3,624,000 after purchasing an additional 67,770 shares in the last quarter. Capital Research Global Investors grew its holdings in Takeda Pharmaceutical by 0.8% during the 3rd quarter. Capital Research Global Investors now owns 13,404,129 shares of the company’s stock valued at $196,236,000 after purchasing an additional 108,556 shares in the last quarter. XY Capital Ltd acquired a new stake in Takeda Pharmaceutical during the 3rd quarter valued at $2,928,000. China Universal Asset Management Co. Ltd. acquired a new stake in Takeda Pharmaceutical during the 4th quarter valued at $998,000. Finally, Sivia Capital Partners LLC acquired a new stake in Takeda Pharmaceutical during the 2nd quarter valued at $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 1.0%

NYSE TAK opened at $15.76 on Tuesday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.27 and a quick ratio of 0.70. The company has a market capitalization of $50.14 billion, a price-to-earnings ratio of 40.40 and a beta of -0.07. The company’s fifty day moving average price is $16.66 and its two-hundred day moving average price is $16.73.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.07%. The firm had revenue of $6.90 billion for the quarter. As a group, research analysts predict that Takeda Pharmaceutical Co. will post 0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TAK shares. Wall Street Zen lowered shares of Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a report on Wednesday, April 29th. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.